A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
← catalyst calendarNCT06935357 · readout in 284 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
454estimated
Sites
258
Countries
Argentina, Australia, Belgium +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-08 | actual | When the study began enrolling |
| Primary completion | 2027-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immunoglobulin A Nephropathy (IgAN)
Interventions
- Drug: Felzartamab — also filed as MOR202, MOR03087, TJ202, HIB202, BIIB148
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR)
measured Baseline up to Week 36
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed